NY-LIME-TRADNG/TKEPROFIT
2.5.2024 14:01:30 CEST | Business Wire | Press release
Lime Trading Corp (“Lime Trading”), a tech-first agency broker headquartered in New York City, proudly announces its strategic partnership with west coast start up TakeProfit, a pioneering community-driven trader platform based in San Francisco, California. This collaboration was born from a joint belief that traders should have access to the best tools and technology no matter their strategy. This new partnership offers retail traders access to the newest innovations in charting and technical analysis, coupled with Lime Trading's industry-leading trade execution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502144682/en/
The newly launched TakeProfit trading platform now offers widgets that integrate seamlessly with Lime Trading. Lime clients will be able to now place trades from the TakeProfit platform and view their portfolio all in one place. (Graphic: Business Wire)
Lime Trading is the only broker connected to TakeProfit, offering exclusive access to a trading widget native to the TakeProfit platform. Now traders can ideate and trade in one, seamless experience without ever leaving the platform. “We are thrilled to introduce this integration with TakeProfit,” remarked Johan Sandblom, CEO at Lime Trading. “By merging Lime Trading's expertise in trade execution with TakeProfit's innovative platform, we are equipping retail traders with the essential tools needed to help navigate today's dynamic markets efficiently.”
Alexey Shulzhenko, TakeProfit’s Founder & CEO said, “We partnered with Lime because they have a passion to build the best for traders, by traders. Their focus on providing all traders with lower latency technology aligns with our mission to bring traders the tools they need to trade more effectively.”
This partnership is just one of a few, recent product enhancements that Lime Trading has released to enhance their retail offering. Most recently they’ve added a Python SDK for their REST API and streamlined their demo paper trading access for traders to test drive Lime for themselves.
Traders wanting to try the TakeProfit trade integration that do not yet have a Lime account to experience this new integration, are able to sign up for a free demo paper account. For more information regarding Lime Trading and TakeProfit's new partnership, visit m.lime.co/takeprofit.
About Lime Trading
For over twenty years, Lime Trading has been focused on developing tools and technology to enhance traders’ access to markets. Focused on lower latency execution, Lime Trading works with retail and institutional clients alike to offer a broad range of APIs, platforms, and technology solutions to traders worldwide. Lime Trading Corp is an SEC-registered broker-dealer, member of FINRA/SIPC/NFA. For more information, visit Lime.co.
About TakeProfit
TakeProfit is a community-driven trading platform equipped with monetization tools for traders. It facilitates sharing research and making better trading decisions, allowing members to capitalize on their expertise. Workspaces are created using widgets, providing a customizable trading environment with immersive charting, custom indicators, screeners, financials, and other tools. TakeProfit brings desktop functionality to the web, utilizing new browser technologies and leveraging the advantages of cloud products. Learn more about TakeProfit at TakeProfit.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502144682/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release
Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom